Stefan Meister is Vice-Chairman and non-executive member of the Board of the Waypoint group, a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family.
Before taking up this role at the start of 2021, he spent close to a decade as Waypoint’s Group Chief Operating Officer.
Prior to that, he was Chief Financial Officer of the Haniel Group, before which he was a member of the Executive Management Board of Celesio Group. He began his career in 1991 at Novartis AG (Switzerland), holding various positions including Head of Controlling for the Pharma Division. Stefan Meister is a Member of the Advisory Board of the Centre for Leadership and Value in Society at the University of St. Gallen, a Member of the “Schweizer Dialog” and an active member of the World Economic Forum’s Family Business Community. Until May 2016, he was a Member of the Board of Directors of the Swiss group, Straumann. Stefan Meister is Swiss and holds a degree in economics from Basel University
Chief Executive Officer
Michele Antonelli is a seasoned biopharmaceutical executive with extensive expertise in both manufacturing and commercial activities.
Michele Antonelli previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities.
Prior to joining UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.
He is Swiss and Italian, and graduated as Doctor in Sciences from University of Bari. He trained in Biotechnology at Catholic University in Piacenza and at Iowa State University in Ames, Iowa.
Francis Crispino’s relevant experience stems from his background as a business founder and investor, senior executive, financier and corporate lawyer:
Co-founder of Greater Pacific Capital; Executive Vice President and Chief Strategy Officer of Bell Canada Enterprises Inc; Goldman Sachs; Sullivan & Cromwell. He studied law at the Univeristy of Oxford and the University of Chicago, and politics and history at the Univeristy of Toronto.
Giampiero De Luca
Dr. Giampiero De Luca is Head of Intellectual Property at Waypoint Capital.
Prior to his appointment with Waypoint Capital, Dr Giampiero De Luca was Vice President Licensing and Intellectual Property of Merck-Serono and Chief Intellectual Property Counsel of Serono International S.A. His responsibilities included management of Serono's patent portfolio, oversight of patent-related litigation and coordinating the Intellectual Property Department's support of the company's licensing activities.
Dr. De Luca began his career at the European Patent Office before joining Serono where he held a variety of positions and responsibilities including the management and coordination of research and development activities, and the establishment of the Corporate Intellectual Property Department in Geneva. Dr. De Luca was also a member of Serono's Executive Management Board.
He holds a doctoral degree in industrial chemistry from the University of Milan, a Diploma in General Microbiology from Institut Pasteur and is a chartered European Patent Attorney, Swiss and Italian Patent Attorney and authorised representative before the Office of Harmonisation in the Internal Market (OHIM).